Aprogen Biologics

(주)에이프로젠바이오로직스 · KOSPI · 003060 · Industry: Manufacture of medicaments

Key metrics

Earnings

Revenue, Q3 2026₩23.2bn As of Sep 30, 2026 Source 1 ↗
Revenue QoQ+0.5% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗
Revenue YoY+9.8% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗
Operating income, Q3 2026-₩7.5bn As of Sep 30, 2026 Source 1 ↗
Operating income QoQ+56.9% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗
Operating income YoY+29.5% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗

Share buybacks

Buyback decided, last 3 months₩0 As of Nov 19, 2026
Buyback decided, last 3 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Shares acquired, last 3 months₩0 As of Nov 19, 2026
Shares acquired, last 3 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Treasury shares cancelled, last 3 months₩0 As of Nov 19, 2026
Treasury shares cancelled (number), last 3 months0 shares As of Nov 19, 2026
Treasury shares cancelled, last 3 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Buyback decided, last 12 months₩0 As of Nov 19, 2026
Buyback decided, last 12 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Shares acquired, last 12 months₩0 As of Nov 19, 2026
Shares acquired, last 12 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗
Treasury shares cancelled, last 12 months₩0 As of Nov 19, 2026
Treasury shares cancelled (number), last 12 months0 shares As of Nov 19, 2026
Treasury shares cancelled, last 12 months, % of shares0.0% As of Nov 19, 2026 Source 1 ↗

Potential dilution

CB/BW/EB issued, last 12 months₩60.8bn As of May 26, 2026 Source 1 ↗, Source 2 ↗
Rights offering new shares, last 12 months14,386,622 shares As of Sep 3, 2026 Source 1 ↗, Source 2 ↗, Source 3 ↗
Potential new shares, last 12 months38,231,890 shares As of Sep 3, 2026 Source 1 ↗, Source 2 ↗, Source 3 ↗, Source 4 ↗, Source 5 ↗
Potential new shares, % of shares265.3% As of Sep 3, 2026 Source 1 ↗, Source 2 ↗, Source 3 ↗, Source 4 ↗, Source 5 ↗ +1 more
Conversion price adjustments, last 12 months0 As of Nov 19, 2026

Supply contracts

Supply contracts, last 12 months₩0 As of Nov 19, 2026
Supply contracts vs prior-year revenue0.0% As of Nov 19, 2026
Contracts without a KRW amount0 contracts without a KRW amount excluded As of Nov 19, 2026

Disclosure activity

DART filings, last 3 months17 As of Nov 19, 2026
DART filings, previous 3 months22 As of Nov 19, 2026

Insider transactions

Open-market buys, last 12 months (shares)0 shares As of Nov 19, 2026
Open-market buys, last 12 months (amount)₩0 As of Nov 19, 2026
Open-market sells, last 12 months (shares)0 shares As of Nov 19, 2026
Open-market sells, last 12 months (amount)₩0 As of Nov 19, 2026
Net open-market buying, last 12 months (shares)0 shares As of Nov 19, 2026
Insiders who bought, last 12 months0 As of Nov 19, 2026

Insider transactions (last 12 months)

Open-market buys: 0 shares (₩0). Open-market sells: 0 shares (₩0). Net open-market buying: 0 shares. Insiders who bought: 0.

Trade dateInsider (role)TypeSharesPriceAmount
Sep 24, 2026Aprogen,Inc. (10%+ shareholder)Other (Exercise price adjustment)+147,484 shares₩2,948₩435m
Sep 23, 2026Aprogen,Inc. (10%+ shareholder)Other (Paid-in new shares)+12,706,481 shares₩1,574₩20.0bn
Aug 29, 2026Aprogen,Inc. (10%+ shareholder)Other (Exercise price adjustment)+972,952 shares₩3,082₩3.0bn
Jul 28, 2026Aprogen,Inc. (10%+ shareholder)Other (Third-party placement)+1,087,548 shares——
Jul 28, 2026Aprogen,Inc. (10%+ shareholder)Other (Exercise price adjustment)+15,886 shares——
May 29, 2026Aprogen,Inc. (10%+ shareholder)Other (Convertible bond acquisition)+2,255,808 shares——
Apr 28, 2026Aprogen,Inc. (10%+ shareholder)Other (Paid-in new shares)+592,593 shares——
Apr 16, 2026G-BAISE Inc. (Controlling shareholder)Other (Reverse split)-47 shares——
Apr 15, 2026Aprogen,Inc. (10%+ shareholder)Other (Capital reduction)-105,308,856 shares——
Apr 15, 2026Kim Jeong-chul (Registered director)Other (Capital reduction)-20,422 shares——
Apr 15, 2026Kang Seong-ho (Registered director)Other (Capital reduction)-11,541 shares——
Apr 15, 2026Kim An-su (Non-registered officer)Other (Capital reduction)-4,493 shares——
Apr 15, 2026Kim Yong-u (Non-registered officer)Other (Capital reduction)-2,196 shares——
Apr 15, 2026Na O-seong (Non-registered officer)Other (Capital reduction)-12,156 shares——

Annual financials

YearRevenueOperating income
2025₩73.2bn-₩60.4bn
2024₩67.4bn-₩52.8bn
2023₩87.4bn-₩57.5bn